Like all Nobel Prize winners, Professor Tasuku Honjo and Professor James Allison have been working for a long time to achieve today\'s results. Professor Honjo\'s team started by studying apoptosis and found programmed death molecule-1 (PD-1) in apoptotic T cells. After long research, they confirmed that mice lacking PD-1 will develop various autoimmune diseases (including lupus-like autoimmune disease, myocarditis, glomerulonephritis, and type 1 diabetes). The coinhibitory signal provided by the PD-1 pathway regulates the T cell activity to avoid an excessive immune response \[[@bib1], [@bib2], [@bib3]\]. In contrast, the tumor cell can escape immune surveillance through activating the PD-1 pathway to suppress the effector T cells. Further research has found that the use of antibodies against these molecules can activate the immune system to destroy cancer cells \[[@bib4]\]. In the beginning, the major pharmaceutical companies did not have much interest, but Professor Honjo persisted so that finally the PD-1 inhibitor became the main drug for immunotherapy. Professor Allison found cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) on T cells in 1995 and established studies focused on B7/cluster of differentiation 28 (CD28)/CTLA-4 \[[@bib5],[@bib6]\]. When CTLA-4 bound to the "B7 family" on the surface of the antigen presenting cell, the T cell was suppressed. This mechanism to regulate the immune response to maintaining self-tolerance can also be misused by cancer cells. Therefore, Professor Allison and his team developed CTLA-4 blockade for cancer treatment and got success in melanoma after 13 years of research \[[@bib7]\]. Professors Honjo and Allison both won the first Tang Award for Biotechnology and Medicine in 2014 \[[@bib8]\]. The two Tang Award winners rely on their enthusiasm for scientific research, their persistence in the research effort, the search for a variety of possible opportunities, and the realization of their theories and achievements. The spirit of perseverance is truly admirable.

Professor Allison\'s research results are mainly used in melanoma, and with anti-PD-1 drugs for the treatment of lung cancer and kidney cancer. Professor Honjo\'s research results have now been widely applied in almost all cancers, including head and neck cancer, lung cancer, liver cancer, stomach cancer, urinary tract cancer, lymphoma, and skin cancer. Clinical trials are also actively undergoing in other cancer types. The combination of two immuno-drugs is more effective, but the side effects are relatively greater. Immunotherapy provides optimistic long-term efficacy compared to traditional chemotherapy or targeted therapy in some patient groups. For example, melanoma is the most widely studied and best-performing disease, with the CTLA-4 immunologic drug (ipilimumab, marketed as Yervoy) successfully allowing 21% of patients to survive for more than 10 years \[[@bib9]\]. Because of the recent development of PD-1 drugs, current official reports have only tracked results for about five years. As of now, though, PD-1 drugs can help 30% of patients with terminal disease survive for more than five years \[[@bib10]\]. The combination of the two drugs has succeeded in allowing more than 50% of patients to survive for more than three years \[[@bib11]\].

After the astonishing improvement reported in melanoma, very many clinical trials have begun in different cancer types, especially in solid cancers with poor prognosis. We list the pivotal trials in \[[Table 1](#tbl1){ref-type="table"}\], and these data shape the landscape of cancer treatment in the early 21st century. Besides malignant melanoma \[[@bib13],[@bib15], [@bib16], [@bib17], [@bib18]\], there have been major advances in renal cell carcinoma \[[@bib24]\], lung cancer \[[@bib26], [@bib27], [@bib28], [@bib29], [@bib30],[@bib32],[@bib33],[@bib38]\], urothelial carcinoma \[[@bib44], [@bib45], [@bib46]\], head and neck squamous cell carcinoma \[[@bib49]\], and triple negative breast cancer \[[@bib59]\]; in these, immune checkpoint inhibitors have become part of the first-line standard treatment. In other cancer types such as hepatocellular carcinoma \[[@bib52], [@bib53], [@bib54]\], gastric/gastroesophageal junctional cancer \[[@bib51]\], colorectal cancer with microsatellite instability--high (MSI-H) or mismatch repair deficient (dMMR) feature \[[@bib55],[@bib56]\], and cervical cancer \[[@bib57]\], immune checkpoint inhibitors play important an role beyond that of first-line therapy. In some rare cancer types with limited effective regimens, such as cutaneous squamous cell carcinoma \[[@bib21]\] and Merkel cell carcinoma \[[@bib22]\], immune checkpoint inhibitors can yield an amazing response rate and median overall survival. Furthermore, the US Food and Drug Administration (FDA) granted accelerated approval to anti-PD-1 (pembrolizumab, marketed as Keytruda) for first tissue-agnostic indication in adult and pediatric patients with advanced MSI-H or dMMR solid tumors beyond first-line \[[@bib58],[@bib59]\]. Furthermore, immunotherapy is moving beyond advanced disease, with studies in consolidation therapy in lung cancer \[[@bib65]\] and adjuvant therapy in melanoma \[[@bib61], [@bib62], [@bib63], [@bib64]\] \[[Table 2](#tbl2){ref-type="table"}\]. We look forward to more positive results in early stage disease that will benefit millions of cancer patients. In conclusion, immune checkpoint inhibitors are writing a whole new chapter in the history of fighting cancer, changing treatment guidelines in many different types of cancer, providing long-term survival, and creating the possibility of a cure for cancer patients who previously had little hope.Table 1Pivotal trials of immune checkpoint inhibitors in different cancer types.Table 1Cancer typeTrial (Phase)Published dateStageLineArmsRR (%)mPFS (months)mOS (months)Ref.Cutaneous melanomaCA184-002 (III)2010Advanced≧2nd lineIpilimumab + gp100\
Ipilimumab\
Gp1006%[x](#tbl1fnx){ref-type="table-fn"}\
11%[x](#tbl1fnx){ref-type="table-fn"}\
2%2.8[x](#tbl1fnx){ref-type="table-fn"}\
2.9[x](#tbl1fnx){ref-type="table-fn"}\
2.810.0[x](#tbl1fnx){ref-type="table-fn"}\
10.1[x](#tbl1fnx){ref-type="table-fn"}\
6.4\[[@bib12]\]CA184-024 (III)2011Metastatic1st lineIpilimumab + DTIC\
DTIC15%\
10%ND[x](#tbl1fnx){ref-type="table-fn"}\
ND11.2[x](#tbl1fnx){ref-type="table-fn"}\
9.1\[[@bib13]\]KEYNOTE-006 (III)2015Advanced≧2nd linePembrolizumab Q2w\
Pembrolizumab Q3w\
Ipilimumab34%[x](#tbl1fnx){ref-type="table-fn"}\
33%[x](#tbl1fnx){ref-type="table-fn"}\
12%5.5[x](#tbl1fnx){ref-type="table-fn"}\
4.1[x](#tbl1fnx){ref-type="table-fn"}\
2.8NR[x](#tbl1fnx){ref-type="table-fn"}\
NR[x](#tbl1fnx){ref-type="table-fn"}\
16.0\[[@bib14],[@bib15]\]CheckMate066 (III)2014Advanced1st lineNivolumab\
DTIC40%[x](#tbl1fnx){ref-type="table-fn"}\
14%5.1[x](#tbl1fnx){ref-type="table-fn"}\
2.237.5[x](#tbl1fnx){ref-type="table-fn"}\
11.2\[[@bib15],[@bib16]\]CheckMate-067 (III)2015\
2017Advanced1st lineNivolumab + Ipilimumab\
Nivolumab\
Ipilimumab57%[x](#tbl1fnx){ref-type="table-fn"}\
44%[x](#tbl1fnx){ref-type="table-fn"}\
19%11.5[x](#tbl1fnx){ref-type="table-fn"}\
6.9[x](#tbl1fnx){ref-type="table-fn"}\
2.9NR[x](#tbl1fnx){ref-type="table-fn"}\
37.6[x](#tbl1fnx){ref-type="table-fn"}\
19.9\[[@bib17],[@bib18]\]CheckMate-037 (III)2015\
2018Advanced≧2nd lineNivolumab\
Chemotherapy[a](#tbl1fna){ref-type="table-fn"}27%[x](#tbl1fnx){ref-type="table-fn"}\
10%3.1\
3.716\
14\[[@bib19],[@bib20]\]Cutaneous Squamous cell carcinomaNCT02760498(I/II)2018Metastatic≧1st lineCemiplimab47%NRNR\[[@bib21]\]Merkel cell carcinomaNCT02267603 (II)2016Advanced1st linePembrolizumab56%67%[b](#tbl1fnb){ref-type="table-fn"}NR\[[@bib22]\]Renal cell carcinomaCheckMate-025 (III)2015Advanced≧2nd lineNivolumab\
Everolimus25%\
5%4.6\
4.425[x](#tbl1fnx){ref-type="table-fn"}\
19.6\[[@bib23]\]CheckMate-214 (III)2018Advanced1st lineNivolumab + ipilimumab\
Sunitinib42%[x](#tbl1fnx){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}\
27%11.6[c](#tbl1fnc){ref-type="table-fn"}\
8.4NR[x](#tbl1fnx){ref-type="table-fn"}^,^[c](#tbl1fnc){ref-type="table-fn"}\
26\[[@bib24]\]Non-small cell lung cancer -NonsquamousCheckMate-057 (III)2015Advanced≧2nd lineNivolumab\
Docetaxel19%[x](#tbl1fnx){ref-type="table-fn"}\
12%2.3\
4.212.2[x](#tbl1fnx){ref-type="table-fn"}\
9.4\[[@bib25]\]KEYNOTE-024 (III)2016\
2018Advanced1st linePembrolizumab\
Platinum-based44.8%[x](#tbl1fnx){ref-type="table-fn"}\
27.8%10.3[x](#tbl1fnx){ref-type="table-fn"}\
6.030[x](#tbl1fnx){ref-type="table-fn"}\
14.2\[[@bib26],[@bib27]\]KEYNOTE-189 (III)2018Metastatic1st linePembrolizumab + chemotherapy[d](#tbl1fnd){ref-type="table-fn"}\
Chemotherapy + placebo47.6%[x](#tbl1fnx){ref-type="table-fn"}\
18.9%8.8[x](#tbl1fnx){ref-type="table-fn"}\
4.9NR[x](#tbl1fnx){ref-type="table-fn"}\
11.3\[[@bib28]\]IMpower-150 (III)2018Metastatic1st lineAtezolizumab + bevacizumab + Chemotherapy[e](#tbl1fne){ref-type="table-fn"}\
Bevacizumab + chemotherapy63.5%[x](#tbl1fnx){ref-type="table-fn"}\
48%8.3[x](#tbl1fnx){ref-type="table-fn"}\
6.819.2[x](#tbl1fnx){ref-type="table-fn"}\
14.7\[[@bib29]\]IMpower130(III)2018Metastatic1st lineAtezolizumab + chemotherapy[f](#tbl1fnf){ref-type="table-fn"}\
Chemotherapy[f](#tbl1fnf){ref-type="table-fn"}49.2%\
31.9%7.0[x](#tbl1fnx){ref-type="table-fn"}\
5.518.6[x](#tbl1fnx){ref-type="table-fn"}\
13.9\[[@bib30]\]Non-small cell lung cancer -SquamousCheckMate-017 (III)2015Advanced≧2nd lineNivolumab\
Docetaxel20%[x](#tbl1fnx){ref-type="table-fn"}\
9%3.5[x](#tbl1fnx){ref-type="table-fn"}\
2.89.2[x](#tbl1fnx){ref-type="table-fn"}\
6.0\[[@bib31]\]\
IMpower 131 (III)20171st lineAtezolizumab + chemotherapy[g](#tbl1fng){ref-type="table-fn"}\
Atezolizumab + chemotherapy[f](#tbl1fnf){ref-type="table-fn"}\
Chemotherapy[f](#tbl1fnf){ref-type="table-fn"}NR\
49%\
41%NR\
6.5[x](#tbl1fnx){ref-type="table-fn"}\
5.6NR\
14.6\
14.3\[[@bib32]\]KEYNOTE-407(III)2018Advanced1st linePembrolizumab + chemotherapy[h](#tbl1fnh){ref-type="table-fn"}\
Chemotherapy + placebo57.6%[x](#tbl1fnx){ref-type="table-fn"}\
38.4%6.4[x](#tbl1fnx){ref-type="table-fn"}\
4.815.9[x](#tbl1fnx){ref-type="table-fn"}\
11.3\[[@bib33]\]Non-small cell lung cancerKEYNOTE-010 (II/III)2016Advanced≧1st linePembrolizumab 2 mg/kg\
Pembrolizumab 10 mg/kg\
Docetaxel30%[x](#tbl1fnx){ref-type="table-fn"}^,^[i](#tbl1fni){ref-type="table-fn"}\
19%[x](#tbl1fnx){ref-type="table-fn"}\
8%5.0[x](#tbl1fnx){ref-type="table-fn"}^,^[i](#tbl1fni){ref-type="table-fn"}\
5.2[x](#tbl1fnx){ref-type="table-fn"}\
4.110.4[x](#tbl1fnx){ref-type="table-fn"}^,^[i](#tbl1fni){ref-type="table-fn"}\
12.7[x](#tbl1fnx){ref-type="table-fn"}\
8.5\[[@bib34]\]OAK (III)2016Advanced≧2nd lineAtezolizumab\
Docetaxel14%\
13%2.8\
4.013.8[x](#tbl1fnx){ref-type="table-fn"}\
9.6\[[@bib35]\]CheckMate-026 (III)2017Advanced≧1st lineNivolumab\
Platinum-based26%[j](#tbl1fnj){ref-type="table-fn"}\
33%4.2[j](#tbl1fnj){ref-type="table-fn"}\
5.914.4[j](#tbl1fnj){ref-type="table-fn"}\
13.2\[[@bib36]\]Small cell lung cancerCheckMate-032 (I/II)2018Limited or extensive stage≧3rd lineNivolumab11.9%1.45.6\[[@bib37]\]IMpower133 (III)2018Extensive stage1st lineAtezolimumab + Chemotherapy[k](#tbl1fnk){ref-type="table-fn"}\
Chemotherapy60.2%\
64.4%5.2[x](#tbl1fnx){ref-type="table-fn"}\
4.312.3[x](#tbl1fnx){ref-type="table-fn"}\
10.3\[[@bib38]\]Urothelial carcinomaKEYNOTE-045 (III)2017Advanced≧2nd linePembrolizumab\
Chemotherapy[l](#tbl1fnl){ref-type="table-fn"}21.1%[x](#tbl1fnx){ref-type="table-fn"}\
11.4%2.1\
3.310.3[x](#tbl1fnx){ref-type="table-fn"}\
7.4\[[@bib39]\]IMvigor211 (III)2018Advanced≧2nd lineAtezolizumab\
Chemotherapy[l](#tbl1fnl){ref-type="table-fn"}23%[m](#tbl1fnm){ref-type="table-fn"}\
22%2.4[m](#tbl1fnm){ref-type="table-fn"}\
4.211.1[m](#tbl1fnm){ref-type="table-fn"}\
10.6\[[@bib40]\]CheckMate-275 (II)2017Advanced≧2nd lineNivolumab19.6%28.74\[[@bib41]\]NCT01693562 (I/II)2017Advanced≧2nd lineDurvalumab27.6%1.518.2\[[@bib42]\]JAVELIN Solid Tumor (I)2017Advanced≧2nd lineAvelumab17%1.66.5\[[@bib43]\]IMvigor210 (II)2017Advanced[n](#tbl1fnn){ref-type="table-fn"}1st lineAtezolizumab23%2.715.9\[[@bib44]\]KEYNOTE-052 (II)2017Advanced[n](#tbl1fnn){ref-type="table-fn"}1st linePembrolizumab28.9%211.5\[[@bib45],[@bib46]\]Head and neck squamous cell carcinomaCheckMate-141 (III)2016Advanced≧2nd lineNivolumab\
Systemic therapy[o](#tbl1fno){ref-type="table-fn"}13.3%\
5.8%2.0[x](#tbl1fnx){ref-type="table-fn"}\
2.37.5[x](#tbl1fnx){ref-type="table-fn"}\
5.1\[[@bib47]\]KEYNOTE-040 (III)2018Advanced≧2nd linePembrolizumab\
Systemic therapy[o](#tbl1fno){ref-type="table-fn"}14.6%\
10.1%2.1\
2.38.4[x](#tbl1fnx){ref-type="table-fn"}\
6.9\[[@bib48]\]KEYNOTE-048 (III)2018Advanced1st linePembrolizumab\
Systemic therapy[p](#tbl1fnp){ref-type="table-fn"}\
Pembrolizumab + platinum+ 5FU23.3%[q](#tbl1fnq){ref-type="table-fn"}\
36.1%\
ND3.4[q](#tbl1fnq){ref-type="table-fn"}\
5.0\
ND14.9[x](#tbl1fnx){ref-type="table-fn"}^,^[q](#tbl1fnq){ref-type="table-fn"}\
10.7\
ND\[[@bib49]\]Gastric cancer /Gastroesophageal junction cancerATTRACTION-2 (III)2017Advanced≧3rd lineNivolumab\
Placebo11%\
0%1.61[x](#tbl1fnx){ref-type="table-fn"}\
1.455.26[x](#tbl1fnx){ref-type="table-fn"}\
4.14\[[@bib50]\]KEYNOTE-059 (II)2018Advanced≧3rd linePembrolizumab11.6%2.05.6\[[@bib51]\]Hepatocellular carcinomaCheckMate-040 (I/II)2017Advanced≧1st lineNivolumab20%[r](#tbl1fnr){ref-type="table-fn"}474%[s](#tbl1fns){ref-type="table-fn"}\[[@bib52]\]KEYNOTE-224 (II)2018Advanced≧2nd linePembrolizumab17%28%[t](#tbl1fnt){ref-type="table-fn"}54%[u](#tbl1fnu){ref-type="table-fn"}\[[@bib53]\]NCT02715531 (Ib)2018Advanced1st lineAtezolizumab + bevacizumab34%14.9NR\[[@bib54]\]Colorectal cancer-d-MMR or MSI-HCheckMate-142 (II)2017Advanced≧2nd lineNivolumab32%14.373%[u](#tbl1fnu){ref-type="table-fn"}\[[@bib55]\]CheckMate-142 (II)2018Advanced≧2nd lineNivolumab + Ipilimumab55%71%[s](#tbl1fns){ref-type="table-fn"}85%[v](#tbl1fnv){ref-type="table-fn"}\[[@bib56]\]Cervical cancerKEYNOTE-158 (II)2018Advanced≧1st linePembrolizumab13.3%2.19.4\[[@bib57]\]Tissue agnostic-dMMR or MSI-HKEYNOTE-016 (II)2017Metastatic≧2nd linePembrolizumab54%53%[w](#tbl1fnw){ref-type="table-fn"}64%[w](#tbl1fnw){ref-type="table-fn"}\[[@bib58]\]KEYNOTE-016, -164, −012, −028, and −1582018Metastatic≧2nd linePembrolizumab39.6%NDND\[[@bib59]\]Breast cancerIMpassion-130 (III)2018Metastatic1st lineAtezolizumab + Nab-paclitaxel\
Nab-paclitaxel56%[x](#tbl1fnx){ref-type="table-fn"}\
46%7.2[x](#tbl1fnx){ref-type="table-fn"}\
5.521.3\
17.6\[[@bib60]\][^1][^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15][^16][^17][^18][^19][^20][^21][^22][^23][^24][^25]Table 2Clinical application of immune checkpoint inhibitors in the adjuvant or consolidation setting.Table 2Cancer typeTrial (Phase)Published dateStageTreatment GoalArmsmRFSmPFSmDMFSmOSRef.MelanomaEORTC 18071 (III)2015\
2016Stage IIIAdjuvantIpilimumab\
placebo26.1\
17.1NA48.3%[a](#tbl2fna){ref-type="table-fn"}\
38.9%65.4%[a](#tbl2fna){ref-type="table-fn"}\
54.4%\[[@bib61]\]\
\[[@bib62]\]CheckMate-238 (III)2017\
2018Resected stage III or IVAdjuvantNivolumab\
ipilimumab62.6%[b](#tbl2fnb){ref-type="table-fn"}\
50.2%NA70.5%[b](#tbl2fnb){ref-type="table-fn"}\
63.7%ND\[[@bib63]\]\
\[[@bib64]\]Non-small cell lung cancerPACIFIC (III)2017Stage IIIConsolidation after CRTDurvalumab\
placebo28.4%[c](#tbl2fnc){ref-type="table-fn"}\
16.0%16.8\
5.623.2[d](#tbl2fnd){ref-type="table-fn"}\
14.6ND\[[@bib65]\][^26][^27][^28][^29][^30]

Although more and more immune drugs are used in various cancer research studies and clinical trials, these drugs also have side effects, including immune-related adverse reactions which differ completely from those of chemotherapy. We should be alert to the early signs of the complications of immunotherapy and treat patients accordingly so to continue to improve the odds of survival.

We should all follow the enthusiastic, dedicated, and persevering spirit of these two pioneers. The inventions of these Nobel Prize winners truly benefit our patients.

Congratulations again to Professor James Allison and Professor Tasuku Honjo for winning the Nobel Prize in Physiology or Medicine.
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[^1]: Abbreviations: RR: Response Rate; mPFS: median Progression-Free Survival; mOS: median Overall Survival; Ref: Reference; ND: not documented; NR: not reported; DTIC: Dacarbazine.

[^2]: Chemotherapy: DTIC or carboplatin/paclitaxel.

[^3]: Progression-free survival rate at 6 months.

[^4]: In intermediate- and poor-risk patients.

[^5]: Chemotherapy: pemetrexed + platinum.

[^6]: Chemotherapy: paclitaxel + carboplatin.

[^7]: Chemotherapy: carboplatin + nab-paclitaxel.

[^8]: Chemotherapy: carboplatin + paclitaxel.

[^9]: Chemotherapy: paclitaxel or nab-Paclitaxel + carboplatin.

[^10]: Among population with a tumor proportion score of ≥50%.

[^11]: Among population with a PD-L1 expression level of ≥5%.

[^12]: Chemotherapy: carboplatin + etoposide.

[^13]: Chemotherapy: paclitaxel or docetaxel or vinflunine.

[^14]: In the IC2/3 population.

[^15]: Cisplatin ineligible.

[^16]: Chemotherapy: Methotrexate, docetaxel, cetuximab.

[^17]: Systemic therapy: platinum+ 5-FU + cetuximab.

[^18]: Combined positive score (CPS) ≧20 population.

[^19]: In the dose-expansion phase.

[^20]: 9-month OS rate.

[^21]: 12-month PFS rate.

[^22]: 6-month OS rate.

[^23]: 12-month OS rate.

[^24]: 24-month PFS and OS rate.

[^25]: Statistically significant compared to control arm.

[^26]: Abbreviations: NA: not applicable; NR: not reached; HR: Hazard Ratio; mRFS: median Recurrence-Free Survival; mPFS: median Progression-Free Survival; mDMFS: median Distant-Metastasis Free Survival; mOS: median Overall Survival; Ref.: Reference; CRT: Chemoradiotherapy.

[^27]: 5-year rate of distant metastasis and overall survival.

[^28]: 24-month rate of recurrence-free survival and DMFS.

[^29]: Response rate.

[^30]: Time to death or distant metastasis.
